Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings Harmony Biosciences Holdings, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: Harmony Biosciences Holdings, Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.61 for the current year.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company has a low valuation given the cash flows generated by its activity.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: Harmony Biosciences Holdings, Inc.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Harmony Biosciences Holdings, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Harmony Biosciences Holdings, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Harmony Biosciences Holdings, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Harmony Biosciences Holdings, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Harmony Biosciences Holdings, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.12B
BB
974B
A
526B
BBB
385B
AA
376B
AA
284B
A
279B
AAA
277B
A
271B
A
187B
A
Average 356.17B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. Ratings Harmony Biosciences Holdings, Inc.